Eversept Partners LP Makes New $14.25 Million Investment in Esperion Therapeutics, Inc. $ESPR

Eversept Partners LP bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 4th quarter, HoldingsChannel reports. The fund bought 3,851,133 shares of the biopharmaceutical company’s stock, valued at approximately $14,249,000.

Several other hedge funds also recently bought and sold shares of ESPR. Jones Financial Companies Lllp purchased a new position in Esperion Therapeutics during the first quarter worth about $278,000. Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth about $25,000. Geode Capital Management LLC lifted its position in shares of Esperion Therapeutics by 3.1% during the second quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock worth $4,513,000 after purchasing an additional 137,691 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Esperion Therapeutics by 16.8% during the second quarter. Rhumbline Advisers now owns 275,688 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 39,658 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Esperion Therapeutics by 93.3% during the second quarter. Invesco Ltd. now owns 493,929 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 238,449 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ESPR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Piper Sandler cut shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Citizens Jmp cut shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Finally, HC Wainwright cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price target on the stock. in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Esperion Therapeutics has an average rating of “Hold” and a consensus target price of $5.54.

Esperion Therapeutics Stock Up 0.3%

Shares of NASDAQ:ESPR opened at $3.17 on Thursday. The firm’s 50 day moving average price is $2.75 and its 200 day moving average price is $3.12. The stock has a market cap of $816.88 million, a price-to-earnings ratio of -52.83, a price-to-earnings-growth ratio of 2.57 and a beta of 1.07. Esperion Therapeutics, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The firm had revenue of $80.10 million during the quarter, compared to analyst estimates of $84.52 million. Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.